Actinium Pharmaceuticals

ATNMPhase 3

Actinium Pharmaceuticals is focused on developing innovative, targeted radiotherapies to address unmet needs in oncology, particularly in hematologic malignancies and solid tumors. The company leverages its expertise with the Actinium-225 payload to create differentiated therapies, with its lead candidates in advanced clinical development. Strategic partnerships, such as the licensing deal with Immedica for Iomab-B in Europe, and collaborations with Astellas and AVEO, support its platform expansion and validate its technology.

Market Cap

$34.6M

Focus

BiologicsRadiopharmaceuticals

ATNM · Stock Price

USD 1.113.98 (-78.19%)

Historical price data

AI Company Overview

Technology Platform

Proprietary platform for developing targeted radiotherapies by conjugating targeting molecules to the potent alpha-emitting radioisotope Actinium-225 (Ac-225), enabling precise delivery of radiation to cancer cells.

Pipeline Snapshot

9 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Iomab-B + Conventional Care	Acute Myeloid Leukemia	Phase 3
131I-apamistamab + Fludarabine + Cyclophosphamide + Allogeneic Hematopoietic Ste...	Acute Leukemia	Phase 2/3
Lintuzumab-Ac225 + Venetoclax + Spironolactone	Acute Myeloid Leukemia	Phase 1/2
Lintuzumab-Ac225 + Venetoclax + Azacitidine	Acute Myeloid Leukemia	Phase 1/2
Cytarabine (Phase 1 only) + Lintuzumab-Ac225 + Furosemide (Phase 1 only) + Spiro...	AML	Phase 1/2

Opportunities

Significant opportunities exist in the large, underserved markets of solid tumors (prostate, lung, breast cancer) and relapsed AML.

The company's Ac-225 platform and partnerships position it to expand into new targets and combinations, while the targeted conditioning approach could be applied to the rapidly growing cell and gene therapy sector.

Risk Factors

Key risks include clinical trial failures, the need for substantial additional capital leading to shareholder dilution, intense competition in the radiopharmaceutical space, and challenges in manufacturing and securing a reliable supply of the Actinium-225 isotope.

Competitive Landscape

Actinium competes with large pharma (Novartis, Bayer) and biotechs in targeted radiotherapy, differentiating through its use of the potent Ac-225 payload and novel targets. In AML, it faces established CD33-targeted therapies but offers a mutation-agnostic, alpha-emitting approach.